As of 2026-09-11, the Intrinsic Value of Cardiol Therapeutics Inc (CRDL.TO) is -1.58 CAD. This CRDL.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.06 CAD, the upside of Cardiol Therapeutics Inc is -151.54%.
Based on its market price of 3.06 CAD and our intrinsic valuation, Cardiol Therapeutics Inc (CRDL.TO) is overvalued by 151.54%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.58 - -1.58 | -1.58 | -151.54% |
| P/E | (2.35) - (3.31) | (2.85) | -193.0% |
| DDM - Stable | (3.04) - (14.39) | (8.71) | -384.8% |
| DDM - Multi | (1.26) - (4.77) | (2.01) | -165.6% |
| Market Cap (mil) | 352.63 |
| Beta | 2.41 |
| Outstanding shares (mil) | 115.24 |
| Enterprise Value (mil) | 325.08 |
| Market risk premium | 5.10% |
| Cost of Equity | 8.62% |
| Cost of Debt | 5.00% |
| WACC | 8.62% |